Drugs / NY-ESO-1 TCR/IL-15 NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06083883 | Mar 2024 → Nov 2026 expected | myxoid/round cell liposarcoma, synovial sarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 TCR/IL-15 NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06083883 ↗ |
| Modality | Cell therapy | “adoptive NK expressing an affinity-enhanced Tcell receptor (TCR)” NCT06083883 ↗ |
| Route | Intravenous | “Given by IV (vein)” NCT06083883 ↗ |